Chymostatin

Chymostatin is a SARS-CoV-2 Mpro inhibitor. Chymostatin up-regulates endocan and inhibits NF-κBp65 activity. Chymostatin reduces proinflammatory cytokines (IL-1β and IL-6) and HMGB1. Chymostatin shows protective effects against Paraquat-induced acute lung injury. Chymostatin exhibits anticancer activity against lung cancer[1][2][3][4][5][6][7].

Product Specifications

CAS Number

[9076-44-2]

UNSPSC

12352209

Target

Interleukin Related; NF-κB; SARS-CoV; Virus Protease

Type

Peptides

Related Pathways

Anti-infection; Immunology/Inflammation; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/chymostatin.html

Purity

99.9

Solubility

DMSO : 50 mg/mL (ultrasonic)

Molecular Weight

607.70

References & Citations

[1]Chen Yang, et al. Protective Effects of Chymostatin on Paraquat-Induced Acute Lung Injury in Mice. Inflammation|[2]Lane JT, et al. Chymostatin inhibits cellular aggregation of activated human peripheral blood lymphocytes. Life Sci. 1980 Aug 11;27 (6) :451-6.|[3]Qiu M, et al. Combination of Chymostatin and Aliskiren attenuates ER stress induced by lipid overload in kidney tubular cells. Lipids Health Dis. 2018 Jul 31;17 (1) :183.|[4]Abstract LB074: Chymostatin, a cathepsin L inhibitor, inhibits lung cancer cell proliferation and COVID-19 Mpro in vitro.|[5]Libby P, et al. Effects of chymostatin and other proteinase inhibitors on protein breakdown and proteolytic activities in muscle. Biochem J. 1980 Apr 15;188 (1) :213-20.|[6]Roszkowska-Chojecka MM, et al. Effects of chymostatin, a chymase inhibitor, on blood pressure, plasma and tissue angiotensin II, renal haemodynamics and renal excretion in two models of hypertension in the rat. Exp Physiol. 2015 Sep;100 (9) :1093-105.|[7]Komatsu K, et al. Beneficial effect of chymostatin on dystrophic mice. Exp Neurol. 1986 Jul;93 (1) :110-6.